Welcome to our dedicated page for Indivior Pharmaceuticals news (Ticker: INDV), a resource for investors and traders seeking the latest updates and insights on Indivior Pharmaceuticals stock.
Indivior PLC (NASDAQ: INDV) generates a steady flow of news centered on its role in treating opioid use disorder (OUD) and on the performance of its key product, SUBLOCADE. Company updates frequently combine clinical, operational, and financial information, reflecting both its pharmaceutical focus and its status as a Nasdaq-listed small-cap healthcare stock.
News coverage commonly includes earnings releases and financial guidance, where Indivior reports net revenue, SUBLOCADE net revenue, non-GAAP operating expenses, and adjusted EBITDA. These announcements often discuss progress under the Indivior Action Agenda, a multi-year operational roadmap that emphasizes U.S. SUBLOCADE growth, organizational simplification, and margin expansion.
Another major news theme is clinical and real-world evidence for SUBLOCADE and long-acting injectable buprenorphine. Indivior regularly reports results from randomized trials and open-label studies published in journals such as JAMA Network Open, as well as poster presentations at professional meetings. These items detail outcomes such as rapid reductions in opioid use, improved treatment retention, differences between maintenance doses, and associations between adherence and healthcare resource utilization.
Investors and healthcare professionals will also find corporate and strategic announcements, including index inclusions like the S&P SmallCap 600, participation in healthcare investor conferences, and steps in the company’s plan to redomicile from the U.K. to the U.S. Regulatory and legal developments, such as the conclusion of a legacy U.S. Department of Justice resolution agreement, are disclosed through press releases and Form 8-K filings.
This news page aggregates these various updates so readers can track Indivior’s financial performance, strategic initiatives, clinical research outputs, and regulatory milestones related to its OUD-focused pharmaceutical business.
Indivior (Nasdaq: INDV) released a cost impact model (March 31, 2026) estimating that monthly injectable buprenorphine (SUBLOCADE) could cut staff time and related costs for treating 100 incarcerated patients with opioid use disorder versus other MOUD options.
The model reported specific staff-hour reductions (318 vs methadone; 747 vs oral buprenorphine; 192 vs weekly extended-release buprenorphine; six vs extended-release naltrexone) and estimated monthly cost savings ranging from $23 to $22,148. The study excluded medication acquisition costs and was funded by Indivior.
Indivior (Nasdaq: INDV) published a national survey of 212 U.S. jails, prisons, and detention centers showing critical access gaps for medications for opioid use disorder (MOUD). Only 58% of facilities offer at least one FDA-approved MOUD, with jails more than twice as likely as prisons to provide treatment.
Regional disparities are stark: western facilities have >3-fold higher odds of offering MOUD than Midwest sites, while the South reports fewer than 10% of diagnosed individuals receiving treatment. Respondents called for better reentry support, telehealth, long-acting injectables, and provider training.
Indivior (Nasdaq: INDV) priced an upsized $450.0 million offering of 0.625% convertible senior notes due 2031, with a 30-day option to purchase an additional $50.0 million.
Net proceeds are estimated at approximately $437.7 million (or ~$486.4 million if option exercised). The initial conversion price is about $41.66 per share, a ~35.0% premium to the March 12, 2026 closing price.
Indivior (Nasdaq: INDV) intends to offer $400 million aggregate principal amount of convertible senior notes due 2031, with a 30-day option for an additional $60 million. Notes will be senior, unsecured, pay semi-annual interest, and may be converted for cash and/or shares.
Indivior expects to use ~$239 million of net proceeds plus ~$102 million cash to repay its term loan and credit facility, up to ~$75 million to repurchase common stock concurrently, and the remainder for general corporate purposes.
Indivior (NASDAQ: INDV) reported a retrospective real-world study published March 11, 2026 linking 12-month adherence to SUBLOCADE (monthly injectable buprenorphine) with substantially lower healthcare use and costs in commercially insured patients with opioid use disorder.
Key result: SUBLOCADE-adherent patients had $15,017 (42%) lower annual non-MOUD medical costs versus patients adherent to other MOUD ($35,761 vs $50,778), plus the lowest inpatient, ED, and detox utilization. Study limitations include observational claims data and COVID-19 overlap.
Indivior (Nasdaq: INDV) reported Q4 and full‑year 2025 results, including record total SUBLOCADE net revenue of $252M (Q4) and $856M (FY), GAAP net income of $102M (Q4) and $210M (FY), and adjusted EBITDA of $142M (Q4) and $428M (FY). The company entered Phase II of its Action Agenda, launched a nationwide DTC campaign, completed U.S. redomiciliation, paid $295M to resolve a legacy DOJ matter, and authorized a $400M share repurchase program. 2026 guidance: net revenue $1,125M–$1,195M; total SUBLOCADE $905M–$945M; adjusted EBITDA $535M–$575M.
Indivior (Nasdaq: INDV) will participate in two investor conferences in Miami in March 2026. CEO Joe Ciaffoni will host 1x1 and group meetings at Barclays 28th Annual Global Healthcare Conference on March 10, 2026 and at Jefferies Biotech on the Beach Summit on March 11, 2026.
Mr. Ciaffoni will join a public fireside chat on March 10 at 2:00 p.m. U.S. EST; interested investors should contact their Barclays or Jefferies representative to schedule meetings. The fireside chat will be available via webcast.
Indivior (Nasdaq: INDV) will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026 at 7:00 a.m. U.S. EST, followed by a live webcast presentation at 8:00 a.m. U.S. EST led by CEO Joe Ciaffoni and the leadership team.
Webcast access, registration details, and a replay will be available in the Investors section of the company website.
Indivior (Nasdaq: INDV) completed redomiciliation from the United Kingdom to the United States effective Jan 26, 2026. A new Delaware parent, Indivior Pharmaceuticals, Inc. (IPI), is now the parent and Indivior PLC was renamed Indivior Ltd. Shareholders received one IPI common share for each Indivior PLC ordinary share as of the scheme record date, and Indivior common stock remains listed on Nasdaq under INDV. IPI is now a U.S. domestic issuer subject to SEC reporting and Nasdaq exchange rules. The redomiciliation was approved at an extraordinary general meeting on Dec 11, 2025.
Indivior (Nasdaq: INDV) provided full-year 2026 financial guidance and a business update. Management expects total net revenue $1,125M–$1,195M, SUBLOCADE net revenue $905M–$945M, non-GAAP operating expenses $430M–$450M, and adjusted EBITDA $535M–$575M for 2026. The company expects SUBLOCADE net revenue growth of ~11% at the midpoint and a ~35% increase in adjusted EBITDA with a 14 percentage-point expansion in adjusted EBITDA margin at the midpoint.
Recent items: completed Phase I of a restructuring program with expected annual non-GAAP OPEX savings of at least $150M, entered Phase II to accelerate dispense-unit growth, gained inclusion in the S&P SmallCap 600, received shareholder approval to re-domicile to the U.S. effective Jan 26, 2026, and paid $295M to conclude a legacy DOJ matter.